LabCorp

LabCorp

Global life sciences R&D services

Oncology Development Executive - Outside Sales

Full-TimeUpdated on 9/26/2026
No salary listed
Mid, Senior, Expert
Bachelor's, Master's, Associate's
Charleston, SC, USA+1 more

More locations: Savannah, GA, USA

In Person

Travel up to 75% within the assigned territory, including overnight stays.

About the job

Requirements
  • High school diploma or GED with 9 years of experience, or an associate degree with 7 or more years of experience, or a bachelor's degree with 5 or more years of experience, or a master's degree with 3 or more years of experience.
  • At least 5 years of business development or outside sales experience selling precision medicine, molecular diagnostics, laboratory services, or related complex diagnostics solutions.
  • At least 3 years of oncology-related commercial experience.
  • Residence in the assigned territory and ability to travel up to 75% within the territory with overnight stays.
  • Valid driver's license and clean driving record.
  • Proven success in new business development, territory growth, competitive conversions, and driving adoption.
  • Consistent record of quota attainment, revenue growth, and new account acquisition.
  • Strong understanding of oncology care pathways, biomarker-driven testing, precision medicine, companion diagnostics, NCCN-guided testing strategies, and EHR/EMR connectivity solutions.
  • Ability to navigate complex healthcare organizations and multi-stakeholder buying processes, with established relationships with oncologists, pathologists, cancer center leaders, genetics programs, and health system stakeholders.
  • Consultative selling, influence, and relationship-building capabilities.
  • Strong presentation skills for communicating scientific concepts to clinical, operational, and executive audiences.
  • Ability to collaborate effectively with cross-functional and matrixed teams.
  • Strong organizational skills, attention to detail, and clinical and business acumen.
  • Experience utilizing Salesforce CRM.
Responsibilities
  • Drive new business acquisition, competitive displacement, market penetration, and revenue growth across oncology practices, pathology groups, cancer centers, health systems, integrated delivery networks, and academic medical centers.
  • Develop and execute territory growth strategies that increase adoption of oncology diagnostics, hereditary cancer, and precision medicine products.
  • Achieve territory revenue, market share, new account, and growth objectives.
  • Maintain accountability for opportunity management, pipeline development, forecasting accuracy, and sales performance through Salesforce CRM utilization.
  • Establish relationships with physician leaders, pathology groups, cancer center administrators, health system stakeholders, and executive decision makers.
  • Lead consultative sales engagements focused on oncology diagnostics, precision medicine adoption, operational efficiency, and testing strategy optimization.
  • Develop enterprise growth plans that expand utilization across health systems, cancer networks, and academic medical centers.
  • Influence testing pathways and adoption strategies within complex healthcare organizations.
  • Represent oncology diagnostics, hereditary cancer, molecular diagnostics, genomic profiling, liquid biopsy, circulating tumor DNA, measurable residual disease, biomarker, next-generation sequencing-based testing, pathology, hematopathology, cytogenetics, and virtual pathology solutions.
  • Translate clinical, genomic, and scientific evidence into business-focused recommendations that support customer decision making.
  • Maintain current knowledge of oncology diagnostics, hereditary cancer testing, molecular diagnostics, genomics, and precision medicine advancements.
  • Coordinate field sales, national accounts, pathology, medical affairs, market access, operations, and executive leadership resources to support growth initiatives.
  • Monitor competitive activity, market trends, and emerging oncology testing opportunities.
  • Drive new business acquisition, competitive displacement, and market share growth across oncology practices, health systems, academic medical centers, pathology groups, cancer centers, and genetics programs.
  • Develop strategic partnerships and advance adoption of oncology diagnostics, hereditary cancer, and precision medicine solutions.
  • Help healthcare organizations implement testing strategies that support precision medicine initiatives and clinical decision making.

About the company

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 10, 2026 investor day reaffirmed 2026 guidance and 5% to 8% annual revenue growth through 2029.
  • MLM Medical Labs expands Labcorp's trial reach in Africa, Germany, and the United States immediately.
  • Labcorp expects Diagnostics and Biopharma Laboratory Services to grow 5.3%-6.5% in 2026.

What critics are saying

  • CMS cuts begin January 1, 2027, and Labcorp faces repeated PAMA reimbursement compression through 2029.
  • The September 4, 2026 website settlement restricts tracking tools like Meta Pixel and Google Analytics for two years.
  • A sustained CMS margin squeeze plus litigation costs can erase growth and force portfolio restructuring.

What makes LabCorp unique

  • Labcorp owns a four-continent central laboratory network after the September 8, 2026 MLM acquisition.
  • Labcorp supported over 85% of FDA-approved new drugs in 2025, per September 2026 materials.
  • Labcorp combines diagnostics, biopharma laboratory services, and biomarker testing under one global platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Yahoo Finance
Sep 22nd, 2026
Labcorp stock drops 3.3% as US cuts Medicare lab reimbursement rates by up to 15%

Labcorp Holdings stock fell 3.3% on Tuesday after the Centers for Medicare & Medicaid Services announced it will cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab work than private insurers. The agency estimates the reduced rates will save taxpayers $1 billion annually. Labcorp derives roughly 8% of its revenue from CMS reimbursement, meaning a full 15% rate reduction would decrease annual revenue by 1.2%. Successive 15% yearly reductions are possible through 2029, implying a worst-case scenario of approximately 3.6% revenue reduction. In its latest SEC filing, Labcorp identified Medicare and Medicaid rate reductions as a key investment risk.

Tech Funding News
Sep 22nd, 2026
Teal Health raises $22M to take FDA-authorised at-home cervical cancer screening mainstream — TFN

Teal Health has raised $22 million in Series A funding, taking its total funding to $45 million as it prepares to expand access to at-home HPV cervical cancer screening.

Beauty Independent
Sep 15th, 2026
Evvy raises $40M to make vaginal microbiome testing routine in women's healthcare

Evvy has raised $40 million in an oversubscribed Series B round led by Catalio Capital to expand its vaginal microbiome platform into reproductive healthcare, focusing on fertility and IVF. The round included U.S. Fertility's Innovation Fund, Labcorp Venture Fund, and existing investors including General Catalyst and Left Lane Capital, bringing total funding to nearly $60 million. The company has served over 100,000 patients and partnered with 3,000 healthcare practitioners, building what it describes as the world's largest proprietary dataset on the vaginal microbiome. Ninety-six percent of patients contribute data anonymously to clinical research. Evvy's at-home Vaginal Health Test analyses over 700 bacteria and fungi using metagenomic sequencing, priced at $159 per test. The funding will scale EvvyAI, the company's data and AI platform underlying its diagnostic services. CEO Priyanka Jain aims to make vaginal microbiome screening routine preventive care, comparable to Pap smears, addressing areas where women's health research has historically been limited.

Business Wire
Sep 12th, 2026
Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A fund...

PR Newswire
Sep 10th, 2026
Labcorp targets 5-8% annual revenue growth through 2029 at investor day

Labcorp hosted its 2026 Investor Day on 10 September, outlining its growth strategy and long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted earnings per share growth of 8.5% to 11.5% through 2029. Chairman and CEO Adam Schechter said Labcorp is positioned at the intersection of diagnostics, biopharma, science and technology. The company reaffirmed its 2026 guidance, projecting enterprise revenue growth of 5.4% to 6.3%. Labcorp's Diagnostics Laboratories division is expected to grow 5.3% to 6.0%, whilst Biopharma Laboratory Services is forecast to grow 5.5% to 6.5%. Chief Financial Officer Julia Wang cited the company's proven delivery record and disciplined value creation framework as underpinning this outlook. The company employs nearly 71,000 people and serves clients in approximately 100 countries.